Скачать или смотреть Gemtuzumab Advancing CD33-Targeted Therapies in AML Research

https://www.assaygenie.com/anti-cd33-...

Key ideas and facts:
What is Gemtuzumab?"Gemtuzumab is an antibody-drug conjugate (ADC) targeting CD33, a protein expressed on the surface of myeloid cells. It is widely recognized for its role in treating acute myeloid leukemia (AML)."
How does Gemtuzumab work?"Gemtuzumab binds to CD33-positive cells and delivers a cytotoxic agent, ozogamicin, to induce cell death specifically in AML cells, sparing healthy tissue."

Approval History:Gemtuzumab was initially approved by the FDA in 2000, withdrawn in 2010, and reapproved in 2017 after new data affirmed its efficacy and safety.
Mechanism of Action (Detailed):The monoclonal antibody component of Gemtuzumab binds to CD33 on AML cells, is internalized, and releases ozogamicin.

"Ozogamicin interacts with the cell’s DNA, causing double-strand breaks that disrupt replication and transcription. This DNA damage ultimately triggers apoptosis, leading to the destruction of the leukemic cell."

This targeted approach reduces off-target effects and systemic toxicity compared to conventional chemotherapies.
Clinical Applications:Gemtuzumab is used in combination with chemotherapy regimens like "3+7" (cytarabine and daunorubicin).

"Clinical trials have demonstrated that incorporating Gemtuzumab into these regimens significantly improves overall survival rates and remission outcomes compared to chemotherapy alone."
It is also used as a standalone treatment for older adults or those who cannot tolerate intensive chemotherapy.

Research is exploring its use in minimal residual disease (MRD) settings to prevent relapse.
Biosimilars:"A biosimilar is a biologic that mirrors the reference product in safety, purity, and potency. Biosimilars foster research by offering affordable access to advanced biological tools, thus driving therapeutic innovation."

Gemtuzumab biosimilars provide researchers with a cost-effective and reliable alternative to the original molecule.
Benefits of biosimilars include consistency, cost-effectiveness, and versatility for diverse research applicationsResearch is exploring its use in minimal residual disease (MRD) settings to prevent relapse.

Biosimilars:"A biosimilar is a biologic that mirrors the reference product in safety, purity, and potency. Biosimilars foster research by offering affordable access to advanced biological tools, thus driving therapeutic innovation."
Gemtuzumab biosimilars provide researchers with a cost-effective and reliable alternative to the original molecule.
Benefits of biosimilars include consistency, cost-effectiveness, and versatility for diverse research applications